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Rationale: Little is known about the longitudinal changes associated with using the 2013 update of the
multidimensional GOLD strategy for chronic obstructive pulmonary disease (COPD).
Objective: To determine the COPD patient distribution of the new GOLD proposal and evaluate how this
classification changes over one year compared with the previous GOLD staging based on spirometry only.
Methods: We analyzed data from the CHAIN study, a multicenter observational Spanish cohort of COPD patients
who are monitored annually. Categories were defined according to the proposed GOLD: FEV1%, mMRC dyspnea,
COPD Assessment Test (CAT), Clinical COPD Questionnaire (CCQ), and exacerbations-hospitalizations. One-year
follow-up information was available for all variables except CCQ data.
Results: At baseline, 828 stable COPD patients were evaluated. On the basis of mMRC dyspnea versus CAT, the
patients were distributed as follows: 38.2% vs. 27.2% in group A, 17.6% vs. 28.3% in group B, 15.8% vs. 12.9% in
group C, and 28.4% vs. 31.6% in group D. Information was available for 526 patients at one year: 64.2% of patients
remained in the same group but groups C and D show different degrees of variability. The annual progression by
group was mainly associated with one-year changes in CAT scores (RR, 1.138; 95%CI: 1.074-1.206) and BODE index
values (RR, 2.012; 95%CI: 1.487-2.722).
Conclusions: In the new GOLD grading classification, the type of tool used to determine the level of symptoms
can substantially alter the group assignment. A change in category after one year was associated with longitudinal
changes in the CAT and BODE index.
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Chronic obstructive pulmonary disease (COPD) is one of
the leading causes of morbidity and mortality worldwide
and is expected to increase over the coming decades [1].
The 2013 Global Initiative for Chronic Obstructive Lung
Disease (GOLD) update proposed important changes to
the stratification of severity in patients with COPD. These
recommendations were based on the evidence that FEV1 is
a partial descriptor of disease status. Therefore, the addition* Correspondence: casanovaciro@gmail.com
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stated.of dyspnea (modified Medical Research Council, mMRC),
health status (COPD Assessment Test, CAT; Clinical
COPD Questionnaire, CCQ), and exacerbations can
achieve a more comprehensive assessment of COPD pa-
tients [1]. However, information on the new classification
is limited because the available information on health sta-
tus is based on the St George’s Respiratory Questionnaire
(SGRQ), which is a surrogate marker for the CAT and no
data has been published about evaluation with tools such
as the CAT or CCQ [2,3]. Most importantly, the annual
longitudinal progression of disease evaluated by the new
GOLD proposal has not yet been explored. Recently,
Agusti and colleagues described the temporal stability ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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mension was assessed only by the mMRC dyspnea [3,4].
Therefore, in the present study, we aimed to evaluate the
distribution of patients in the CHAIN cohort, a prospective
Spanish multicenter study with multidimensional evalu-
ation of COPD patients, according to the 2013 update of
the GOLD classification. We focused on the different distri-
butions according to the tools used to evaluate the symp-
toms domain (mMRC, CAT, and CCQ) [3]. To determine
the potential implications in clinical practice, we analyzed
changes in the new GOLD classification at one year, explor-
ing its temporal stability compared to changes in the old
GOLD 2007 classification at one year.
Methods
Subjects
COPD patients participating in this study were part of the
COPD History Assessment In SpaiN (CHAIN) cohort.
CHAIN is a multicenter study of 36 prospective cohorts
carried out at university hospitals in Spain [3]. COPD was
defined by smoking history ≥10 pack-years and a post-
bronchodilator FEV1/FVC <0.7 after 400 μg of inhaled
albuterol. Patients were stable for at least 8 weeks and
receiving optimal medical therapy. Exclusion criteria were:
uncontrolled co-morbidities such as malignancy at base-
line or other confounding diseases that could interfere
with the study. Others methodological aspects of the study
were published previously [5]. The recruitment period
was January 15, 2010, to March 31, 2012 (ClinicalTrials.
gov Identifier: NCT01122758). Patients are currently in the
follow-up period, but the data analyzed in the present study
came from the baseline and one-year follow-up appoint-
ments. December 15, 2012, was used as the cut-off date for
the longitudinal data.
Briefly, at baseline and each annual visit, we evaluated
anthropometric data (age, gender, and BMI), comorbidities
(Charlson index; scale 0-33), smoking history, dyspnea
(mMRC 0-4 scale), exacerbations during the previous year,
quality of life according the Spanish versions of the CAT
(scale 0-40) [6] and CCQ (scale 0-60) [7], anxiety and
depression [Hospital anxiety (scale 0-21) and depression
(scale 0-21) HAD scale] [8], treatments, respiratory func-
tion (arterial blood gases, spirometry, lung volume, and CO
diffusion capacity), exercise capacity (six minute walking
distance, 6MWD), and BODE index (scale 0-10). Data was
anonymized in a database with hierarchical access control
in order to guarantee secure information access. All par-
ticipants signed the informed consent form previously ap-
proved by each of the ethics committee in the participating
centers.
Clinical and physiological measurements
In a personal interview, trained staff obtained the follow-
ing information at the time of recruitment and at yearlyappointments: age, gender, and the body mass index (BMI).
BMI was calculated as the weight in kilograms divided
by height in meters. A specific questionnaire was used
to determine smoking status (current or former) and
smoking history (pack-years). The presence of comorbidi-
ties was evaluated by the Charlson index [9].
Pulmonary function tests were performed following
ATS guidelines [10]. The diffusion capacity for carbon
monoxide (DLCO) was determined by the single breath
technique following the ERS/ATS guidelines [11]. We
have used the European Coal and Steel Community [12]
predictive equations as reference values for lung function
parameters. PaO2 was measured at rest in the sitting pos-
ition while breathing room air. The 6MWD test measured
the better of two walks separated by at least 30 minutes
[13]. Dyspnea was evaluated by the mMRC scale [14]. The
FEV1%, BMI, 6MWD, and MMRC values were integrated
into the BODE index as previously described [15]. Exacer-
bations were defined by use of antibiotics, steroids, or
both or admission to the hospital related to worsening re-
spiratory symptoms. We registered the number of subjects
with ≥2 exacerbations/yrs or ≥1 hospitalization/yr.
Statistical analysis
Data are summarized as relative frequencies for categorical
variables, mean and standard deviation (SD) for normally
distributed scale variables, and median and 5th − 95th per-
centile for ordinal or non-normal scale variables. Compari-
sons were made between groups using Pearson chi-square,
Kruskal-Wallis H test, Mann-Whitney U test, one-way
ANOVA, Student t-test or Mantel-Cox test, according to
the variable type and distribution. The concordance among
the symptoms questionnaires was estimated by Cohen’s
Kappa index. In order to determine the association between
worsening GOLD category classification and changes in
FEV1, BODE index values, and clinical parameters, we ob-
tained ROC type-II curves and estimated the C-statistics
for each one. Finally, we performed multivariate logistic
regression analysis to determine the main factors at base-
line associated with worsening at 12 months in the GOLD
category classifications. Significance was established as
a two tailed P < 0.05. Calculations were performed using
SPSS 20.0 (Chicago, USA).
Results
Study population
A total of 828 patients with COPD were evaluated at
baseline. The clinical and physiological characteristics of
these patients are shown in Table 1. The population was
mainly male (83%) and included a broad range of patients
with airflow obstruction: 140 mild (16.9%), 403 moderate
(48.7%), 188 severe (22.7%), and 97 very severe (11.7%).
Patients reported low level of symptoms and had few
hospital admissions during the previous year. Around
Table 1 Baseline patient characteristics
Variable Patients
(N = 828)
Gender (M/F)* 687 / 141
Age (y) 67 (9)
Pack-years 56 (28)
Active smoking* 29%
BMI (kg/m2) 28.1 (5.5)
FEV1L 1.65 (0.65)
FEV1% 56 (28)
PaO2 (mmHg) 67.4 (9.6)
FVC L 3.130 (0.94)
FVC% 88 (19)
FEV1/FVC 53 (11)
6MWD (m) 438 (104)
Dyspnea (mMRC)† 1 (0-4)
BODE index† 4 (0-6)
IC/TLC 0.35 (0.10)
KCO 74 (24)
Charlson index† 1 (0-5)
Exacerbations ≥2 per patient-years‡ 0.15 (0.01)
Hospitalization ≥1 per patient-years‡ 0.12 (0.01)
Inhaled anticholinergic* 75%
Inhaled β2-agonist* 74%
Inhaled corticosteroid* 65%
CAT† 11 (2-27)
CCQ† 1,3 (0-3.7)
Data presented as mean (SD) unless otherwise noted.
*Number and/or percent.
†Median (P5-95).
‡In the year before enrollment.
Figure 1 Distribution of patients in the 2013 GOLD
classification using all of the symptom measurements.
Table 2 Baseline characteristics by GOLD risk groups
GOLD 2013
Variable A B C D p
Gender (M/F)* 125 / 22 255 / 59 35 / 5 272 / 55 0.632
Age 66 (8) 68 (9) 68 (9) 68 (9) 0.030
Pack-yr 50 (24) 55 (27) 51 (28) 60 (29) 0.006
Active smoking* 40% 38% 28% 25% 0.001
BMI (kg/m2) 27.9 (4.7) 28.7 (6.2) 27.6 (4.6) 27.9 (5.1) 0.155
6MWD m 474 (97) 450 (98) 428 (93) 400 (108) <0.001
BODE index† 0 (0-2) 1 (0-4) 2 (0-7) 3 (0-7) <0.001
Charlson index† 1 (0-5) 1 (0-5) 1 (0-4) 1 (0-5) 0.263
Inhaled anti
cholinergic*
56% 68% 87% 88% <0.001
Inhaled β2-agonist* 53% 68% 88% 90% <0.001
Inhaled
corticosteroid*
45% 55% 82% 83% <0.001
Theophylline* 0.7% 5% 10% 17% <0.001
Data presented as mean (SD) unless otherwise noted.
*Number and/or percent.
†Median (P5-95).
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a similar percentage used β2-agonist. In general, the
patients have a normal BMI, exercise capacity, and a
few comorbidities.
Baseline distribution for the 2013 GOLD update
Using the all scores (mMRC dyspnea, CAT, CCQ) included
in the new GOLD 2013 classification to evaluate symptoms
as a combined form (patients were moved to B or D
score if one of these reached the cut-off point of each
score: ≥2, ≥10, >1 respectively), the distribution of patients
was as follows: 147 (17.8%) in group A, 314 (37.9%) in
group B, 40 (4.8%) in group C, and 327 (39.5%) in group
D (Figure 1). Most patients (54.1%) classified in groups C
and D were categorized as such because of low FEV1
values, 22.4% because they had frequent exacerbation
or one hospitalization during the previous year, and
23.5% because of a combination of both criteria: FEV1
and exacerbation during the previous year.The clinical characteristics are shown in Table 2. A
higher percentage of patients in categories A and B were
actively smoking, and those in grade A were slightly youn-
ger, than those in the other groups. The patients in C and
D categories walked less, had a higher BODE index and
received more pulmonary pharmacological therapy.
Figure 2 shows the classification of patients according to
the 2007 (I to IV) and 2013 (A to D) GOLD classifications.
The new GOLD criteria resulted in more patients being
characterized into the most severe group (327 in category D)
compared to the old criteria (97 in stage IV).
Category assignment was similar using the CAT and
CCQ scores, but changed when the mMRC scale was
used (Table 3). The largest disagreement in reassignment
of patients was observed in groups A and B. According
Figure 2 Distribution of patients with COPD at baseline according to GOLD 2007 and GOLD 2013 classification.
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lower and more individuals remained in group A. When
a combination of these different tools was used to evalu-
ate symptoms, changes in the distribution of patients
were shown with an increased number of individuals in
categories B and D (Figure 1).
The concordance between the different tools used to
evaluate symptoms in GOLD 2013 classification was:
mMRC and CAT, қ: 0.534, P < 0.001; mMRC and CCQ,
қ: 0.490, P < 0.001; CAT and CCQ, қ: 0.673, P < 0.001. The
concordance index among the use of one symptom score or
the addition of three was low: mMRC (қ: 0.578, P < 0.001);
CAT (қ: 0.738, P < 0.001); CCQ (қ: 0.747, P < 0.001). How-
ever, this concordance improved around 0.90 when two
scores were used, regardless of the tools chosen.
No differences in comorbidities as evaluated by
the Charlson index were found among categories A-D
(P = 0.263). The proportion of patients with reportedTable 3 Tools used to evaluate 828 patients at baseline
based on 2013 GOLD classification
GOLD 2013 A B C D
mMRC 316 (38.2%) 146 (17.6%) 131 (15.8%) 235 (28.4%)
CAT 214 (27.2%) 223 (28.3%) 102 (12.9%) 249 (31.6%)
CCQ 220 (26.6%) 241 (29.1%) 117 (14.1%) 250 (30.2%)heart disease was greater in groups B and D but was
not significant (A: 10.1%, B: 15.2%, C: 8.7%, D: 16.1%).
However, more patients in groups B and D had HAD
scores ≥11 than those in groups A and C (anxiety: A, 43%;
B, 80.4%; C, 38.9%; D, 69.8%; depression: A, 21%; B, 47.8%;
C, 21.1%; D, 49%; P < 0.001).
Longitudinal (1 year) GOLD data
At the time of the analysis, complete information except
for the CCQ was available for 526 patients at one year.
Patients excluded from the longitudinal analysis showed
similar baseline data for age (67.7 vs. 67.3 years, p = 0.307),
gender (84% vs. 82% males, p = 0.446), level of FEV1
(58% vs. 60%, p = 0.140), and GOLD categories (A 18.5%
vs 17.6.%, p = 0.371; B 34.3% vs 40.2%, p = 0.138; C 4.6%
vs 5.2%, p = 0.709; D 43.6% vs 37.1%, p = 0.068).
Figure 3 shows the percentage of patients classified
as GOLD A to D using mMRC and CAT symptoms
measurements as a combined form at baseline and one
year later. Longitudinal changes in the population were
as follows: 64.4% of patients remained in the same cat-
egory. The variability was greater for group C and lower
for group D (50% and 28.6%, respectively). These annual
longitudinal changes in the new GOLD classification
exhibited greater variability and very low concordance
compared to the old GOLD classification (қ: 0.326,
P < 0.001; Figures 4A and 4B).
Figure 3 The annual longitudinal changes by GOLD stage comparing the 2007 and 2013 versions (using mMRC dyspnea and CAT in a
combined form). We considered worsening and improving in the 2013 GOLD classification the shift from A to D and from D to A
groups respectively.
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erbations and ≥1 hospitalization during the first year were
as follow respectively: 3,3% and 0% in group A, 6,7% and
0,6% in group B, 8,7% and 8,7% in group C, 12,8% and
5,2% in group D (p <0.001). The subanalysis between B
and C groups only shown statistical significant differences
in percent of patients with ≥1 hospitalization (p = 0.003)
but not with ≥2 COPD exacerbations (p = 0.544).
The ROC analysis showed that worsening (change in
grading from to any other grade: A-B, A-C, A-D, B-C, B-
D, C-D) of the new GOLD stratification at one year was
independently associated with longitudinal changes in the
following parameters: mMRC (C-statistic 0.690, 95%
CI 0.604-0.777, P < 0.001), CAT (C-statistic 0.716, 95%
CI 0.631-0.802, P < 0.001), FEV1% (C-statistic 0.669,
95% CI 0.580-0.758, P < 0.001), BODE index (C-statistic
0.745, 95% CI 0.672-0.818, P < 0.001), and depression
(C-statistic 0.608, 95% CI 0.518-0.698, P = 0.026). We
did not find a significant association of changes in stratifica-
tion with exacerbation, comorbidities, anxiety, or pulmon-
ary inhaler treatment. The results of adjusting the logistic
binary model over the potential predictors of worsening
GOLD categories changes after one year are shown in
Table 4. The BODE index and CAT scores remained the
most important and independent predictors of changes in
GOLD categories: 2.012 (95% CI: 1.487-2.722) for BODE
index and 1.138 (95% CI: 1.074-1.206) for CAT.
Discussion
This observational study of COPD patients who attended
pulmonary clinics has several important findings. First, we
described the distribution of patients evaluated by the new2013 GOLD classification with all of the parameters
recommended by the strategy, confirming that the type
of tool used to determine symptoms domain can substan-
tially alter group assignment. Second, compared to the old
2007 GOLD classification, this new multidimensional
evaluation classified a higher number of patients into
more severe categories. Third, we showed that longitudinal
one-year changes in groups A to D are associated with one-
year changes in the CAT score and the BODE index. This
novel data supports the role of symptoms and the multidi-
mensional BODE index in the evaluation of patients with
COPD. Finally, after one year of follow-up, one-third of
patients changed groups; the longitudinal change was
greater and had a low concordance compared to the old
GOLD classification.
This study confirms that a small proportion of patients
are classified into group C (low symptoms and high risk)
[2], but most importantly, we confirmed that the use of
different tools to evaluate symptoms (dyspnea mMRC
vs. health status with the CAT or CCQ) significantly
modifies grade assignment. The new GOLD strategy
recommends that is unnecessary to use more than one
scale for symptom evaluation. However, it is not sup-
ported by adequate scientific evidence and it is unclear
whether they can be used in an additive manner [1].
Previous studies based on existing data from different
cohorts recently provided information about the new
GOLD classification [2,3,16-19]. All of the studies used
the mMRC to evaluate symptoms and only one also used
the SGRQ (as a surrogate for the CAT) to determine the
patient’s grade [2]. The results were similar to those of
the present study. This result is not surprising, as CAT
Figure 4 Longitudinal changes in the CHAIN cohort. (A). Proportion of patients assigned to groups A-D (GOLD 2013 using mMRC dyspnea
and CAT in a combined form) at baseline and the one-year follow-up. (B). Proportion of patients assigned to groups I-IV (GOLD 2007) at baseline
and the one-year follow-up.
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Table 4 Relative risk of annual worsening of GOLD 2013 categories using univariate and multivariate logistic binary
regression modeling
Variable Univariate analysis
Relative risk 95%CI p
Age 1.032 1.004-1.062 0.027
Gender (female) 1.542 0.761-3.122 0.229
Active smoking 1.086 0.637-1.853 0.761
BMI 1.021 0.983-1.060 0.280
Inhaled β2-agonist 0.824 1.487-1.393 0.470
Inhaled anticholinergic 0.905 0.529-1.550 0.717
Inhaled corticosteroid 1.065 0.639-1.774 0.809
Charlson index 1.047 0.898-1.220 0.557
Anxiety 1.021 0.967-1.077 0.450
Depression 1.096 1.027-1.170 0.006
FEV1%* 1.065 1.034-1.096 <0.001
mMRC* 1.956 1.494-2.562 <0.001
CAT* 1.162 1,106-1.221 <0.001
Exacerbations ≥2 or hospitalization ≥1* 0.981 0.182-5.285 0.982
BODE index* 2.136 1.664-2.742 <0.001
Multivariate analysis
Relative risk 95%CI p
CAT 1.138 1.074-1.206 <0.001
BODE index 2.012 1.487-2.722 <0.001
*The variables are included in the multivariate logistic regression model with constant using the backward stepwise method and Wald’s criteria adjusted at
four iterations.
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and have not demonstrated a strong correlation with the
dyspnea determined by the mMRC. Han et al. suggested
that potential changes can occur in the stratification of pa-
tients according to the metric used to evaluate symptoms,
which our data confirmed. Importantly, we observed that
the change in category assignment was greater with the
CAT or CCQ compared to the SGRQ used in the previous
study. In addition, we performed a novel analysis to evalu-
ate the assignment of patients to categories if two or three
symptom scores are determined in an additive form. The
results showed an important shift of patients to the B and
D groups, which could have implications on the recom-
mendations for therapy. However, taking into account
the concordance index, two metric symptoms appear to
be enough and an adequate alternative to evaluating
symptom dimensions with the new GOLD classification.
Our results indicate that the best schema could include
the mMRC and the CAT or CCQ. This approach captures
information related to important outcomes, such as
mortality with mMRC [20], avoiding disagreement and
redundant data.
Similar to previous studies, more patients in our cohort
were assigned to more severe stages with the new classi-
fication compared to the old classification [2,3,16-19].However, Lange et al. showed that the prognosis of
group D is worse if the patients are stratified by FEV1
compared to the frequency of exacerbation [15]. In our
study, the number of patients categorized into this last
group (D2: 22.4%) was higher than in previous studies,
even one study performed in a similar clinical setting [2].
An explanation is the use of one hospitalization as the risk
criteria according to the new GOLD strategy.
One of the major strengths of the present study is that it
reports longitudinal data. To the best of our knowledge,
we are reporting the first prospective information regarding
the new GOLD A to D groups and their annual change.
Approximately two-thirds of patients remained in the
same category. Little differences were found by groups,
though we observed greater variability for group C and
lower variability for group D. This pattern shows some
differences from the analysis of the ECLIPSE cohort,
which also exhibited important variability in group B.
However, this previous study evaluated the temporal
stability after 3 years and only used the mMRC for
symptom assessment [3].
Annual changes in most individuals were on the hori-
zontal axis according to the new GOLD stratification and
associated with changes in symptoms. Although one point
change in the mMRC dyspnea scale is known to predicts
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changes in the CAT score [21].
Regarding annual changes on the vertical axis (risk) of
the new GOLD approach, only a few patients changed
from the A and B to the C and D categories, but 12-15%
of patients in the C or D categories changed to the A or B
categories. In general, changes by group were greater with
the new GOLD strategy than with the old GOLD strategy,
and the concordance was low. Currently, the importance
of these annual changes by grade remains unknown. The
clinical application of the new GOLD classification in the
clinical practice remains unclear and more data with this
proposed approach are needed.
Another important finding in the longitudinal changes
in the new GOLD stratification is that these changes
were best predicted by the BODE index. The predictive
power of this index was superior to the mMRC and
FEV1% alone, and it can be explained, in part, by a com-
posite score such as the BODE index better integrating
the changes in these variables over time.
Our study has several limitations. First, the CHAIN
cohort was obtained from an observational study of pa-
tients attending pulmonary clinics and not from a general
medical practice or population-based study. Therefore,
the cohort might not represent the true distribution of
COPD severity in the general population. However, our
cohort included a broad range of disease severity, includ-
ing 17% of patients in GOLD I with low mean symptom
scores. Second, few women were included in the cohort,
and the findings reported here cannot be extended to
that gender. Nevertheless, the distribution of women into
GOLD categories was similar to that of men. In addition,
the main results remain unchanged when we performed a
stratified subanalysis of the population by gender. Third,
we have not described outcomes, such as mortality; at the
time of the analysis this was not the main objective and
the patients are currently being followed up.
In summary, our data based on a large cohort of
well-characterized COPD patients provide important
information on the assessment of patients with COPD.
Using all parameters included in the new multidimen-
sional GOLD classification, we confirmed that more pa-
tients are classified into severe categories compared to
the old GOLD classification. Furthermore, we showed
that the choice of tool for evaluating symptoms could
alter the group assignment. According to our findings,
the GOLD strategy should probably better define the
thresholds by the symptoms approach, including the
mMRC and CAT or CCQ. Finally, we reported the an-
nual progression of groups A to D for the first time.
The new GOLD classification is more flexible regard-
ing category changes over time, and these changes are
mainly associated with longitudinal changes in the CAT
score and BODE index.Appendix
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